Company CVAbout Coral Laboratories Ltd 
Coral Laboratories Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Coral Laboratories Limited (CLL) was established in February, 1997. It was promoted by Navin B Doshi of the DWD Group. To manufacture pharmaceutical formulations like tablets, capsules, liquid and topical preparation, the Company came up with a public issue in March, 1994 by raising funds of Rs.2.5 Crore. It setup an additional ultra-modern manufacturing unit at Daman and the said Unit started the commercial production during March 2004.
Company Coordinates
Company Details
SF-206 Silver Oak Complex, BPC Road Vadodara Gujarat : 390020
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR None Cr
Number of Shares
None Cr
Face Value
INR None
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
No Details Available.
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Chetan Navinchandra Doshi (51.54%)
Highest Public shareholder
Meeta Samir Sheth (1.84%)
Individual Investors Holdings
20.52%
Board of Directors
Management
Designation
Remuneration
Sheela R Kamdar
Independent Director
0
Girish Dhameja
Whole-time Director
28.13 lacs
Sushma Shashi Kadkade
Director & CFO
0
Saurabh Shah
Independent Director
0
Ruchi Anjaria
Company Sec. & Compli. Officer
0
Malay Doshi
Independent Director
0
Rajendrasinh Rana
Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical Products
89.87
97.19%
Other Operating Revenue
2.60
2.81%
Pharmaceutical Products
Pharmaceutical Products
Other Operating Revenue
Other Operating Revenue
Stock DNARevenue and Profits:
Net Sales:
19 Cr
(Quarterly Results - Sep 2025)
Net Profit:
6 Cr
Pharmaceuticals & Biotechnology
INR 164 Cr (Micro Cap)
9.00
32
0.34%
-0.48
8.29%
0.74
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
